Fortress Biotech, Inc. (FBIO) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FBIO Revenue Growth
Revenue Breakdown (FY 2024)
FBIO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
FBIO Revenue Analysis (2013–2024)
As of May 8, 2026, Fortress Biotech, Inc. (FBIO) generated trailing twelve-month (TTM) revenue of $62.3 million, reflecting exceptional growth of +20.5% year-over-year. The most recent quarter (Q3 2025) recorded $17.6 million in revenue, up 7.4% sequentially.
Looking at the longer-term picture, FBIO's 5-year compound annual growth rate (CAGR) stands at +9.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $187.6 million in 2017.
Revenue diversification analysis shows FBIO's business is primarily driven by Qbrexza (49%), Accutane (38%), and Amzeeq (10%).
When compared to Healthcare sector peers including XOMA (+126.2% YoY), RCUS (+67.4% YoY), and ROIV (-56.4% YoY), FBIO has underperformed the peer group in terms of revenue growth. Compare FBIO vs XOMA →
FBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FBIOCurrent | $62M | +20.5% | +9.5% | -191.4% | |
 XOMA | $52M | +126.2% | +12.2% | 21.8% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 ROIV | $29M | -56.4% | -15.6% | -3453.3% | |
 MNOV | $409,657 | - | - | -3242.5% |
FBIO Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $57.7M | -31.8% | $36.8M | 63.8% | $-110,379,000 | -191.4% |
| 2023 | $84.5M | +11.6% | $61.6M | 72.9% | $-142,342,000 | -168.4% |
| 2022 | $75.7M | +10.1% | $45.0M | 59.4% | $-203,564,000 | -268.8% |
| 2021 | $68.8M | +50.9% | $36.7M | 53.4% | $-188,541,000 | -274.1% |
| 2020 | $45.6M | +24.5% | $31.0M | 68.0% | $-94,270,000 | -206.7% |
| 2019 | $36.6M | +36.3% | $26.1M | 71.2% | $-110,819,000 | -302.5% |
| 2018 | $26.9M | -85.7% | $20.8M | 77.2% | $-119,997,000 | -446.4% |
| 2017 | $187.6M | +1038.3% | $26.4M | 14.1% | $-89,796,000 | -47.9% |
| 2016 | $16.5M | +1809.6% | $5.1M | 31.1% | $-65,710,000 | -398.7% |
| 2015 | $863K | - | $863K | 100.0% | $-50,531,000 | -5855.3% |
See FBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFBIO — Frequently Asked Questions
Quick answers to the most common questions about buying FBIO stock.
Is FBIO's revenue growth accelerating or slowing?
FBIO revenue is accelerating at +20.5% year-over-year, exceeding the 5-year CAGR of +9.5%. TTM revenue reached $62M. Growth momentum has increased versus prior periods.
What is FBIO's long-term revenue growth rate?
Fortress Biotech, Inc.'s 5-year revenue CAGR of +9.5% reflects the sustained expansion pattern. Current YoY growth of +20.5% is above this long-term average.
How is FBIO's revenue distributed by segment?
FBIO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.